Price Alert

Supernus Pharmaceuticals ... (SUPN)

NASDAQ: SUPN · Real-Time Price · USD

42.69

0.52 (1.23%)

At close: Aug 15, 2025, 3:59 PM

42.69

0.01%

After-hours: Aug 15, 2025, 04:54 PM EDT

Supernus Pharmaceuticals Statistics

Share Statistics

Supernus Pharmaceuticals has 56.07M shares outstanding. The number of shares has increased by 1.6% in one year.

Shares Outstanding	56.07M
Shares Change (YoY)	1.6%
Shares Change (QoQ)	0.31%
Owned by Institutions (%)	99.99%
Shares Floating	53.24M
Failed to Deliver (FTD) Shares	488
FTD / Avg. Volume	0.07%

Short Selling Information

The latest short interest is 5.1M, so 9.13% of the outstanding shares have been sold short.

Short Interest	5.1M
Short % of Shares Out	9.13%
Short % of Float	13.82%
Short Ratio (days to cover)	7.43

Valuation Ratios

The PE ratio is 26.97 and the forward PE ratio is 17.12. Supernus Pharmaceuticals's PEG ratio is 0.

PE Ratio	26.97
Forward PE	17.12
PS Ratio	3.01
Forward PS	2.9
PB Ratio	1.92
P/FCF Ratio	11.64
PEG Ratio	0

Financial Ratio History

Enterprise Valuation

Supernus Pharmaceuticals has an Enterprise Value (EV) of 1.96B.

EV / Sales	2.96
EV / EBITDA	10.98
EV / EBIT	11.38
EV / FCF	11.43

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.03.

Current Ratio	2.35
Quick Ratio	2.16
Debt / Equity	0.03
Debt / EBITDA	0.19
Debt / FCF	0.2
Interest Coverage	0

Financial Efficiency

Return on Equity is 7.13% and Return on Invested Capital is 5.69%.

Return on Equity	7.13%
Return on Assets	5.4%
Return on Invested Capital	5.69%
Revenue Per Employee	$981.92K
Profits Per Employee	$109.59K
Employee Count	674
Asset Turnover	0.48
Inventory Turnover	1.43

Taxes

Income Tax	24M
Effective Tax Rate	24.53%

Stock Price Statistics

The stock price has increased by 25.16% in the last 52 weeks. The beta is 0.74, so Supernus Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.74
52-Week Price Change	25.16%
50-Day Moving Average	33.4
200-Day Moving Average	34.35
Relative Strength Index (RSI)	78.09
Average Volume (20 Days)	735,272

Income Statement

In the last 12 months, Supernus Pharmaceuticals had revenue of 661.82M and earned 73.86M in profits. Earnings per share was 1.34.

Revenue	661.82M
Gross Profit	583.91M
Operating Income	81.67M
Net Income	73.86M
EBITDA	178.28M
EBIT	97.87M
Earnings Per Share (EPS)	1.34

Full Income Statement

Balance Sheet

The company has 69.33M in cash and 34.27M in debt, giving a net cash position of 35.06M.

Cash & Cash Equivalents	69.33M
Total Debt	34.27M
Net Cash	35.06M
Retained Earnings	556.43M
Total Assets	1.38B
Working Capital	452.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 171.95M and capital expenditures -725K, giving a free cash flow of 171.23M.

Operating Cash Flow	171.95M
Capital Expenditures	-725K
Free Cash Flow	171.23M
FCF Per Share	3.11

Full Cash Flow Statement

Margins

Gross margin is 88.23%, with operating and profit margins of 12.34% and 11.16%.

Gross Margin	88.23%
Operating Margin	12.34%
Pretax Margin	14.79%
Profit Margin	11.16%
EBITDA Margin	26.94%
EBIT Margin	12.34%
FCF Margin	25.87%

Dividends & Yields

SUPN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	3.71%
FCF Yield	8.59%

Dividend Details

Analyst Forecast

The average price target for SUPN is $41, which is 1.1% higher than the current price. The consensus rating is "Hold".

Price Target	$41
Price Target Difference	1.1%
Analyst Consensus	Hold
Analyst Count	2

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$6.7
Lynch Upside	-83.47%
Graham Number	23.81
Graham Upside	-41.27%

Scores

Altman Z-Score	6.01
Piotroski F-Score	6